PBAC's latest decision on Thyrotropin alfa: Recommended with restriction (2007). Considered for preparation for radioiodine ablation of thyroid remnant tissue in adult post thyroidectomy patients without known metastatic disease who are/will be maintained on hormone suppression therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$45k/QALY
$15k/QALY–$45k/QALY · across 2 submissions
Submissions
2
first 2006
Submissions
2
2006 → 2007
Eligible population
adult post thyroidectomy patients without known metastatic disease who are/will be maintained on hormone suppression therapy, in the ablation of thyroid remnant tissue
Therapy area
Endocrinology
Evidence base
RCT
Primary endpoint
Ablation success
Key trials
THYR-008-00-00, Hanscheid et al Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study
Comparator
withholding/withdrawing thyroid hormone therapy for 4–6 weeks prior to ablation (induced hypothyroidism)
Economic model
CUA
ICER basis
Range aggregates 2 submissions (2006–2007) — not a single base case.
Submission history
Jul 2006: Not recommended · Authority Required — ICER $45k/QALY
Mar 2007: Recommended with restriction · Authority Required — ICER $45k/QALY